Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090903 · ClinicalTrials.gov registry record · NA
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
A NA study of Glioblastoma and Recurrent Glioblastoma, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06090903 is a NA study of Glioblastoma and Recurrent Glioblastoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 50 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06090903, a NA study of Glioblastoma and Recurrent Glioblastoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the United States. Glioblastoma is a type of malignant glioma with very poor patient prognosis. There are currently only about 3 drugs approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma, one of them being administration of bevacizumab, which is very expensive. It is the most widely used treatment for glioblastoma with dramatic results. However, previous clinical trials have not demonstrated an overall survival benefit across all patient populations with glioblastoma that has returned after treatment (recurrent). The study aims to identify which patients who will benefit from bevacizumab therapy by observing MRI images and corresponding imaging biomarkers.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- OTHER Medical Chart Review
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2028-04-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06090903
The ClinicalTrials.gov registry entry for NCT06090903 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (54% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT06090903 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06090903 about?
NCT06090903 is a clinical study titled "Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma". This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the Unit...
What is the current status of trial NCT06090903?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2022-04-14. Estimated completion is 2028-04-18.
What conditions does trial NCT06090903 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Resectable Glioblastoma.
What interventions are being tested in trial NCT06090903?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Medical Chart Review (OTHER).
Who is sponsoring clinical trial NCT06090903?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090903 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
RECRUITING · NA
-
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.